Buy Rating Reaffirmed: CorMedix Inc. (CRMD) Posts Profitability and Expands Outlook for 2025

CorMedix Inc. (NASDAQ:CRMD) is one of the champion breakout stocks to put in. On November 13, H.C. Wainwright’s Brandon Folkes reaffirmed a Buy connected CorMedix Inc. (NASDAQ:CRMD), citing beardown DefenCath-driven revenue, Melinta acquisition synergies, and aggregate maturation catalysts including Rezzayo and TPN Phase 3 information successful 2026. Despite TDAPA pricing risks, robust financials and pipeline imaginable enactment a favorable semipermanent outlook.

A stethoscope. Photo by Pixabay

On November 12, CorMedix Inc. delivered beardown third-quarter results, underscoring request for specialty injectable therapies. It posted $104.3 cardinal successful nett gross and $130.8 cardinal successful pro forma nett revenue, driven by higher utilization of DefenCath by outpatient dialysis customers.

Likewise, the institution bounced backmost to profitability, generating $108.6 cardinal successful nett income, oregon $1.26 per share. It was an betterment from a nett nonaccomplishment of $2.8 million, oregon $0.05 per share, delivered successful the aforesaid 4th past year. Growth successful nett income was driven by nett merchandise income and a one-time taxation payment of $59.7 million.

CorMedix is betting connected DefenCath, an FDA-approved catheter fastener solution that offers important hazard simplification successful catheter-related bloodstream infections (CRBSI). Consequently, it has raised its full-year 2025 pro forma nett gross to betwixt $390 cardinal and $410 million. It besides expects nett gross to scope betwixt $115 cardinal and $135 million. Following the acquisition of Melinta Therapeutics, the institution expects to seizure $30 cardinal successful synergy.

CorMedix Inc. (NASDAQ:CRMD) is simply a biopharmaceutical institution focused connected processing and commercializing therapeutic products for infectious and inflammatory diseases. Its pb merchandise is DefenCath, an antimicrobial catheter fastener solution utilized to forestall catheter-related bloodstream infections successful hemodialysis patients.

While we admit the imaginable of CRMD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 13 Best AI Stocks to Buy Under $20 and Top 6 Steel Stocks to Buy Amid US Tariffs.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.